Combination Therapy With Beta‐Blockers and Angiotensin‐Converting Enzyme Inhibitors for Cardiovascular Diseases: Focus on Bisoprolol/Ramipril
Cardiovascular Therapeutics · 2026-01 · 2026 (1)
DOI: 10.1155/cdr/6773898 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cardiovascular Therapeutics, online erschienen am 27.05.2026. Verfasst von Agostino Virdis. Beteiligte Einrichtung: Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy, unipi.it. Hauptthemen laut MEDLINE: Angiotensin-Converting Enzyme Inhibitors, Cardiovascular Diseases, Antihypertensive Agents, Ramipril. Die Arbeit nennt 126 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Sandoz, Università di Pisa, CRUI - CARE.
Abstract (Originalsprache)
Patients with hypertension, especially when complicated by cardiovascular disease (CVD) and/or comorbidities, require long‐term treatment with a combination of antihypertensive drugs, which often gives rise to complex drug regimens. Dual‐agent combination antihypertensive therapy is recommended in most patients with hypertension, and where available, a fixed‐dose single‐pill combination (SPC) is recommended. The combination of antihypertensive drugs should take into account the patient′s overall CVD risk profile (other CVD risk factors and diagnoses). The combination of a beta‐blocker and angiotensin‐converting enzyme inhibitor (ACEi) acts on two neuroendocrine systems implicated in the pathophysiology of hypertension and multiple CVD: beta‐blockers on the sympathetic nervous system and ACEis on the renin–angiotensin system (RAS). A large body of solid evidence states that, in addition to their antihypertensive effects, both beta‐blockers and ACEis provide cardioprotection and guarantee reductions in CV morbidity and mortality in patients with coronary artery disease (CAD), atrial fibrillation, and heart failure. For these reasons, such a combination might be beneficial for many patients. This review summarizes the evidence supporting the use of beta‐blockers and ACEis, as well as the rationale behind their combined administration, particularly in patients with a high risk of CVD, such as those with ischemic heart disease, atrial fibrillation, or heart failure.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy, unipi.it.
ORCID-Profile: Agostino Virdis
Förderung
- Sandoz
- Università di Pisa
- CRUI - CARE
Zitieren
APA
Virdis, A. (2026). Combination Therapy With Beta‐Blockers and Angiotensin‐Converting Enzyme Inhibitors for Cardiovascular Diseases: Focus on Bisoprolol/Ramipril. Cardiovascular Therapeutics, 2026(1). https://doi.org/10.1155/cdr/6773898
Vancouver
Virdis A. Combination Therapy With Beta‐Blockers and Angiotensin‐Converting Enzyme Inhibitors for Cardiovascular Diseases: Focus on Bisoprolol/Ramipril. Cardiovascular Therapeutics. 2026;2026(1). doi:10.1155/cdr/6773898
BibTeX
@article{Virdis2026,
author = {Virdis, Agostino},
title = {Combination Therapy With Beta‐Blockers and Angiotensin‐Converting Enzyme Inhibitors for Cardiovascular Diseases: Focus on Bisoprolol/Ramipril},
journal = {Cardiovascular Therapeutics},
year = {2026},
volume = {2026},
number = {1},
doi = {10.1155/cdr/6773898}
}
EUVIMED